...
首页> 外文期刊>Journal of Drug Assessment >Medication adherence and graft survival among heart transplant recipients
【24h】

Medication adherence and graft survival among heart transplant recipients

机译:心脏移植受者的药物依从性和移植物存活

获取原文
           

摘要

Background: Though medication adherence is essential for graft survival, little is known about the impact of non-adherence on heart transplant survival. Aims: The objective of this study was to examine the association between graft survival and adherence in heart transplant recipients. Methods: This retrospective, observational cohort study used claims data from a single, large national pharmacy chain (claims data from 2013-2016) and post-transplant follow-up data from the OPTN database (data from post-transplant to 2016). The sample included adult, deceased-donor heart transplant recipients (most recent if more than one) who had &2 pharmacy claims for any immunosuppressant &150?days apart in the 12-months after their first fill in the study period (2013–2016). Proportion of days covered (PDC) by any immunosuppressant for 12-months after first fill was calculated as a measure of adherence (defined as PDC &80%). Graft survival was defined as having a surviving graft at the end of the study period. Logistic regression was used to estimate the association between adherence and graft survival controlling for covariates (age at transplant, time since transplant, gender, race/ethnicity, copay, number of prescriptions for chronic conditions, pharmacy insurance plan, brand medication usage, digital fills, filling at a transplant specialized pharmacy, and receiving financial assistance). Results: Of the 3,435 heart transplant recipients who were eligible for the study, 75% were adherent and 81% had a surviving graft (range?=?6–10,012?days post-transplant; median?=?1,409?days). After adjusting for covariates, the odds of having a surviving graft were almost double for adherent patients than for non-adherent patients (OR?=?1.94 [95% CI?=?1.58–2.37]; p ?&?0.001). Other notable factors associated with graft survival included having three or fewer post-index prescriptions for chronic conditions (OR?=?4.33 [3.55–5.27]; p ?&?0.001) and filling immunosuppressants digitally (OR?=?2.25 [1.13–4.48]; p ?&?0.001). A sensitivity analysis using a PDC &90% as the definition for adherence showed that the odds of having a surviving graft were 2.01 (95% CI [1.67–2.43]) times more likely for adherent patients. Conclusions: This analysis suggests adherent patients had greater odds of having a surviving graft than those who were not adherent to immunosuppressants. Future studies should aim to show which patient behaviors contribute to medication adherence and what PDC threshold should be used for transplant research.
机译:背景:尽管坚持药物治疗对于移植物生存至关重要,但对于坚持移植对心脏移植生存的影响知之甚少。目的:本研究的目的是检查心脏移植受者的移植物存活率与依从性之间的关系。方法:这项回顾性观察性队列研究使用了来自单个大型国家药房链的索赔数据(2013-2016年的索赔数据)和来自OPTN数据库的移植后随访数据(从移植后到2016年的数据)。样本中包括成年的,已死亡的供者心脏移植受者(如果有一个以上,则是最近的),他们在第一次填写研究期后的12个月内,在两次免疫药疗中,在150天内相隔2次以上的药理要求(2013年) –2016)。计算首次填充后12个月内任何免疫抑制剂覆盖的天数(PDC)的比例作为依从性的量度(定义为PDC≥80%)。移植物存活定义为在研究​​期结束时有存活的移植物。使用Logistic回归估计协变量(移植年龄,移植后时间,性别,种族/民族,共付额,慢性病处方数量,药房保险计划,品牌药物使用,数字填充)的依从性和移植物存活控制之间的关联,在移植专科药房加药并获得经济资助)。结果:在符合条件的3,435名心脏移植受者中,有75%坚持了治疗,有81%的患者存活了下来(移植后天数== 6-10,012天;中位数== 1,409天)。调整协变量后,依从性患者存活的移植物的几率几乎比非依从性患者高(OR≤1.94 [95%CI≤1.58–2.37]; p≤0.001)。与移植物存活相关的其他显着因素包括针对慢性病制定三个或三个以下指数后处方(OR≥4.23[3.55-5.27]; P <0.001)和以数字方式填充免疫抑制剂(OR≥2.25[1.13])。 –4.48]; p <0.001。使用PDC> 90%作为依从性定义的敏感性分析表明,对于依从性患者,存活的移植物的几率高2.01倍(95%CI [1.67–2.43])倍。结论:该分析表明,与不依从免疫抑制剂的患者相比,依从性患者拥有存活的移植物的几率更高。未来的研究应旨在表明哪些患者的行为有助于药物依从性,以及将哪个PDC阈值用于移植研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号